T1	p 27 61	eastern cooperative oncology group
T2	p 147 210	2000 patients with stage IIB and III melanoma have participated
T3	p 214 230	four multicenter
T4	p 607 619	April 2001 .
T5	p 709 717	patients
T6	p 721 756	E1684 , E1690 , E1694 , and E2696 .
T7	p 837 929	713 patients randomized to high-dose IFN-alpha 2b ( HDI ) or Obs in Trials E1684 and E1690 .
T8	p 1525 1530	E1684
T9	p 1537 1553	age > 49 years .
T10	p 1776 1817	patients with high-risk resected melanoma
T11	i 96 116	high-dose interferon
T12	i 340 379	adjuvant high-dose IFN-alpha 2b therapy
T13	i 864 894	high-dose IFN-alpha 2b ( HDI )
T14	i 898 901	Obs
T15	i 1353 1356	HDI
T16	o 563 571	Survival
T17	o 576 590	disease status
T18	o 1196 1263	relapse-free survival ( RFS ) -but not overall survival ( OS ) -was
T19	o 1449 1452	RFS
T20	o 1457 1459	OS
T21	o 1469 1502	ulceration , recurrent disease at
T22	o 1654 1665	RFS benefit
T23	o 1722 1732	OS benefit
T24	o 2036 2043	relapse
T25	o 2087 2104	therapeutic value